GEN News Highlights: Jul 29, 2010

EMD Millipore Licenses Tissue-Staining Method from Cleveland Clinic

(Page 1 of 1)

    EMD Millipore has obtained rights to a technique for protein research from Cleveland Clinic. The new method is intended to reduce the time required for staining tissue sections from 12 hours to 30 minutes.

    The technique was developed using Millipore's SNAP i.d.® Protein Detection System. Scientists at Millipore and Cleveland Clinic are in the process of validating the method for diverse tissue types and fixation protocols.

    “By reducing tissue analysis time to minutes, the SNAP i.d. system can increase research throughput and speed up protocol optimization, enabling researchers to make faster decisions about their results,” comments Don O’Neil, director of product management at Millipore.

    The SNAP i.d. system from Millipore uses vacuum to actively drive reagents through membrane-fixed tissue sections. This reportedly increases exposure of tissue antigens to blocking reagents, antibodies, and wash buffers. Traditional tissue staining involves mounting sections on glass slides and relies on diffusion for reagent permeation through the sections.

    EMD Millipore was born out of Merck KGaA’s $7 billion acquisition of Millipore. It was announced in March and completed in July. EMD Millipore is the life science division, combing Merck’s EMD Chemicals business in New Jersey with Millipore. It is known as Merck Millipore outside the U.S. and Canada.


Related content

GEN News Highlights

Insight & Intelligence™

GEN Articles

Webinars

GEN Podcasts

New Products

Best of the Web

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll